DENVER -- Patients with advanced kidney cancer treated with immune checkpoint inhibitors (ICIs) lived longer if they consumed a high-fiber diet, a small prospective study showed. The investigators ...

Many medicines are available to treat kidney cancer. If one treatment doesn’t help or stops working, your health care provider may recommend another option. If you or a loved one has kidney cancer and ...

A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers ...

Fotivda monotherapy may match or outperform combination therapy in metastatic renal cell carcinoma, offering comparable progression-free survival and objective response rates. The 2025 ASCO Annual ...

Cancer is still the most common cause of death for men in the US ages 60 to 79 and women ages 40 to 79. For all adults ...

Kidney cancer in early stages is curable if found and treated before it spreads. Surgery is a common treatment for stages 1 to 3 kidney cancer and can remove part or all of the kidney. Stage 4 kidney ...

– Zanzalintinib in combination with nivolumab demonstrated an objective response rate of 63% and a disease control rate of 90% – – Additional results from dose-finding cohorts will also be presented – ...

Fruzaqla and Tyvyt combination significantly improved progression-free survival and response rates in advanced renal cell carcinoma patients compared to standard monotherapies. The FRUSICA-2 trial ...

Exelixis (EXEL) announced an update on their ongoing clinical study.

DENVER -- Planned treatment "holidays" can help lessen the toxicity burden of tyrosine kinase inhibitors (TKIs) for selected patients with advanced kidney cancer without harming treatment efficacy, ...

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.